Eli Lilly and Company
COMBINATION THERAPY FOR CANCER WITH EXON 14 SKIPPING MUTATION(S) OR EXON 14 SKIPPING PHENOTYPE
Last updated:
Abstract:
The present invention provides preparation of medicaments for use in treating and methods of treating cancer with tumors with MET exon 14 skipping mutation(s) or MET exon 14 skipping phenotype with emibetuzumab, in combination, as described herein, with merestinib.
Status:
Application
Type:
Utility
Filling date:
10 Nov 2017
Issue date:
16 Sep 2021